<DOC>
	<DOC>NCT00191243</DOC>
	<brief_summary>Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine. Aim of the study is to assess the optimal dosage and safety in this setting.</brief_summary>
	<brief_title>Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>histologically verified diagnosis of breast carcinoma, at first diagnosis restricted previous adjuvant chemotherapy (completed &gt;6 months prior the study) measurable and/or nonmeasurable disease previous radiotherapy is allowed if:terminated at least 10 days prior the sudy therapy, at least one target lesion for evaluation of tumor response has not been irradiated performance status 02 (WHO, Zubrod) adequate bone marrow reserve defined adequate liver / renal functions defined any prior systematic chemotherapy for metastatic breast cancer expected survival time less than 12 weeks past or current history of malignant neoplasm other than breast carcinoma except for cured nonmelanoma skin cancer or curatively treated in situ carcinoma of the cervix uteri known brain metastases/leptomeningeal involvement active uncontrolled infection symptomatic peripheral neuropathy &gt; grade 2 according to NCI patients whose lesions are assessable only by radionuclide scan or patients with sclerotic bone lesions as the only site of disease concomitant illness that is contraindication to the use of corticosteroids other concomitant serious illness or medical condition, which may worsen due to the treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>